Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis. Dermatology Reports, [S. l.], v. 17, n. 1, 2024. DOI: 10.4081/dr.2024.9999. Disponível em: https://journals.pagepress.org/dr/article/view/9999. Acesso em: 19 jun. 2025.